检索结果 - Hanfei Qi
- Showing 1 - 2 results of 2
-
1
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial 由 Mark C. Markowski, Mary‐Ellen Taplin, Rahul Aggarwal, Laura A. Sena, Hao Wang, Hanfei Qi, Aliya Lalji, Victoria J. Sinibaldi, Michael A. Carducci, Channing J. Paller, Catherine H. Marshall, Mario A. Eisenberger, David E. Sanin, Srinivasan Yegnasubramanian, Carolina Gomes‐Alexandre, Büşra Özbek, Tracy Jones, Angelo M. De Marzo, Samuel R. Denmeade, Emmanuel S. Antonarakis
出版 2024Artigo -
2
Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells 由 Jun-Ke Wang, Jessica Gai, Tengyi Zhang, Nan Niu, Hanfei Qi, Dwayne L. Thomas, Keyu Li, Tao Xia, Christina M. Rodriguez, Rose Parkinson, Jennifer N. Durham, Thomas McPhaul, Amol Narang, Robert A. Anders, Arsen Osipov, Hao Wang, Jin He, Daniel A. Laheru, Joseph M. Herman, Valerie Lee, Elizabeth M. Jaffee, Elizabeth D. Thompson, Qingfeng Zhu, Lei Zheng
出版 2024Artigo
相关主题
Cancer
Immunotherapy
Internal medicine
Medicine
Oncology
Adverse effect
Antibody
CD8
Cancer research
Clinical endpoint
Clinical trial
Immune system
Immunology
Monoclonal antibody
Myeloid
Nivolumab
Overall survival
Pancreatic cancer
Phases of clinical research
Progression-free survival
Prostate cancer
Radioimmunotherapy
Testosterone (patch)
Tolerability
Tumor microenvironment
Urology